Grit Otto-Moritz is not sitting in the treatment room at Helios Hanseklinikum Stralsund for the first time. The 60-year-old agricultural engineer was diagnosed with breast cancer back in 2013. At the end of 2025, she was diagnosed with lung cancer; she has overcome both diseases. In mid-January, however, another serious diagnosis followed: the former breast cancer had metastasized and spread to her bones.
At Helios Hanseklinikum Stralsund, her medical history is therefore being reviewed once again in its entirety. Findings are reassessed, assumptions questioned—nothing can be overlooked now. For her treating physician, Dr. med. Hussein Abdallah, Senior Consultant in General, Thoracic and Visceral Surgery, diagnostic precision is paramount. The patient experiences firsthand that at Helios, doctors do not look at individual diagnoses in isolation, but focus on identifying connections.
Her story is emblematic of many people affected by cancer, particularly patients with complex or multiple diagnoses. It illustrates why individualized cancer care is crucial—and why World Cancer Day offers an opportunity to reassess this commitment time and again.
Fresenius’ role – cancer care along the entire patient journey
On World Cancer Day, Fresenius highlights its contribution to cancer care and shows how colleagues across the company work every day to support people living with cancer in the best possible way.
Fresenius accompanies patients throughout all phases of their disease. Fresenius Kabi, Helios and Quirónsalud provide care that brings together medical treatment, innovative medical products, modern technologies and supportive services.
Support ranges from prevention and early detection to diagnostics and personalized therapies, acute clinical treatment, as well as aftercare, long-term follow-up and palliative or home-based care.
At the center is always the person—patients as well as employees. Physicians, nurses, therapists, researchers and many other professional groups jointly take responsibility for cancer care that is individualized and reliable.
Fresenius Kabi: Efforts tailored to address the changing needs and challenges faced by cancer patients
Cancer rarely follows a straight path—and neither does care. Therapy phases change, recovery occurs in waves. This reality repeatedly confronts patients with new challenges. Fresenius Kabi employees align their work precisely with this reality.
In addition to tumor treatment itself, this includes reducing side effects and pain, maintaining physical strength.
Fresenius Kabi contributes to this with a broad portfolio of treatments and services. This includes biologic medicines and essential drugs used in both treatment and supportive care.
These are complemented by infusion technologies, devices and technical expertise that ensure safe and reliable administration.
Biosimilars improve security of supply and access to effective targeted therapies, particularly for complex and multiple cancer conditions. Another key component is clinical nutrition, which supports patients whose nutritional status is impaired by illness or therapy.
Clinical oncology at Helios – individualized care for complex diseases
At Helios, cancer treatment is also far more than a single therapy. Across more than 90 hospitals nationwide, every course of treatment begins with a careful review of the patient’s medical history and current life situation. Based on this, specialized teams develop individually tailored treatment concepts. Helios draws on the expertise of a nationwide network of certified cancer centers.
Grit Otto-Moritz’s story shows how important this approach is. Dr. med. Hussein Abdallah explains: “When a patient has already had multiple cancer diagnoses, particularly careful evaluation of all findings is essential to ensure that an additional tumor is not overlooked. In interdisciplinary tumor conferences, colleagues from different specialties contribute their expertise to define the best possible treatment.”
Priv.-Doz. Dr. med. Daniel Pink, Head of the Oncology Center at Helios, also emphasizes the importance of close collaboration: “The best treatment outcomes for the diverse and often complex cancer diseases are achieved through close interdisciplinary cooperation among many experts. At Helios, we also work closely with office-based physicians during follow-up care.”
March 11, 2026
Miami, USA
Barclays 28th Annual Global Healthcare Conference
March 11 – 12, 2026
A face in front of a screen. A brief glance at a painting. A barely perceptible twitch of the facial muscles; subtle changes in skin response; the eyes lingering on specific details of the image. These subtle cues, which often go unnoticed in everyday life, are precisely captured in the research project “Emociones a través del arte.” In May 2024, Quirónsalud, our Spanish hospital business, launched the project in collaboration with Museo Nacional Thyssen-Bornemisza and Universidad Rey Juan Carlos, both in Madrid. The central question was: What emotions does art trigger in us? And can this impact be measured objectively and quantitatively? This was the first scientific study of its kind.
Over a period of eight weeks, researchers examined the reactions of 127 individuals, including patients form Quirónsalud. Selected paintings from different periods and various collections of the museum were presented to them digitally. Using a range of methods, the researchers analyzed which visual elements attracted particular attention and which emotions the artworks evoked in viewers.
The results are clear: color, composition, and lighting play a decisive role in influencing emotions in measurable ways. Some images produced surprisingly consistent emotional responses, while others defied common expectations. And: some works predominantly triggered positive emotions, while others exclusively elicited negative ones. The study thus provides solid, data-based evidence for the long-debated assumption: that art does not only work subjectively, but can deliberately influence viewers’ emotional states, with potential implications for well-being and health.
Relevant here is that the individuals came into contact with the artworks exclusively within the framework of the study, i.e., in a controlled research environment.
“The experiences of our patients are a central component of our understanding of health. Initiatives such as the ‘Emociones a través del arte’ project not only help us to deepen our knowledge based on scientific evidence. They also open up entirely new perspectives, enabling us to continuously work towards excellence in care and improving people’s well-being,” says Dr. Cristina Caramés, Quirónsalud's Director of Healthcare and Research.
The results of the research project, published in spring 2025, by no means mark the end of the investigation. Plans include further analysis of the collected data and translating it into various formats, such as scientific publications or digital applications, as well as using it for new research approaches. The aim is to deepen understanding of the precise relationship between art, emotion, and health.
In the longer term, this is expected to open up new ways of making the positive effects of art accessible to patients – in a structured, evidence-based manner.
Whether in a scientific setting or in everyday hospital care, both Quirónsalud initiatives follow the same conviction: health encompasses more than just medical parameters and guideline-based treatment. Emotional stability and people’s subjective sense of well-being are equally important factors, particularly in the context of serious illness. Quirónsalud therefore combines innovative research and professional practice. Art thus becomes a building block of an expanded, holistic understanding of health.
https://www.museothyssen.org/en/special/emotions-art
General Terms and Conditions of Purchase in German
SAP and Fresenius today announced that both companies intend to enter a strategic partnership to accelerate innovation for stronger digital healthcare delivery. Together, the companies plan to create the digital backbone for a sovereign, interoperable, and AI-supported healthcare system. The solutions will combine the expertise of Fresenius, one of the world’s largest healthcare companies, with future-oriented SAP technologies and meet high requirements for data sovereignty, security, and regulatory compliance. The plan is to provide an open, integrated, and data‑driven digital health ecosystem that enables hospitals and medical facilities worldwide to use AI securely and to handle health data responsibly.
Digital sovereignty for healthcare
SAP and Fresenius plan to jointly build an individual, scalable healthcare platform that enables connected, data-driven healthcare processes. Based on this, the companies will develop joint, future-oriented, and AI-supported healthcare solutions to sustainably increase quality, transparency, and efficiency across the entire care chain and set new standards for digital innovation in the healthcare sector. The foundation will be proven SAP technologies and products such as SAP Business Suite, SAP Business Data Cloud (SAP BDC), SAP Business Technology Platform (SAP BTP), and SAP Business AI. These core elements help create a unified, compliant, open, and expandable base for the more-secure exchange and use of data as well as for operating AI models in a controlled environment.
Together, the companies also plan to build a sovereign, European solution for an integrated healthcare ecosystem that supports the integration of modern hospital information systems (HIS) based on SAP’s “AnyEMR” strategy. Interfaces based on open industry standards such as HL7 FHIR will enable the more-seamless connection of HIS, electronic medical records (EMRs), and other medical applications.
“Together with SAP, we can accelerate the digital transformation of the German and European healthcare systems and enable a sovereign European solution that is so important in today’s global landscape. We are making data and AI everyday companions that are secure, simple, and scalable for doctors and hospital teams. This creates more room for what truly matters: caring for patients,” says Michael Sen, CEO of Fresenius.
“With SAP’s leading technology and Fresenius’ deep healthcare expertise, we aim to create a sovereign, interoperable healthcare platform for Fresenius worldwide. Together, we want to set new standards for data sovereignty, security, and innovation in healthcare. Thanks to SAP, Fresenius can harness the full potential of digital and AI-supported processes and sustainably improve patient care,” says Christian Klein, CEO and Member of the Executive Board of SAP SE.
As part of the joint transformation project, both companies plan to invest a mid three-digit million euro amount in the medium term to consistently drive the digital transformation of the German and European healthcare system through the use of digital and AI-supported solutions.
The partnership is implemented through several forms of collaboration. These include joint investments in startups and scaleups, joint technological developments, and close cooperation within coordinated governance structures between the two companies.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
SAP and Fresenius today announced that both companies intend to enter a strategic partnership to accelerate innovation for stronger digital healthcare delivery. Together, the companies plan to create the digital backbone for a sovereign, interoperable, and AI-supported healthcare system. The solutions will combine the expertise of Fresenius, one of the world’s largest healthcare companies, with future-oriented SAP technologies and meet high requirements for data sovereignty, security, and regulatory compliance. The plan is to provide an open, integrated, and data‑driven digital health ecosystem that enables hospitals and medical facilities worldwide to use AI securely and to handle health data responsibly.
Digital sovereignty for healthcare
SAP and Fresenius plan to jointly build an individual, scalable healthcare platform that enables connected, data-driven healthcare processes. Based on this, the companies will develop joint, future-oriented, and AI-supported healthcare solutions to sustainably increase quality, transparency, and efficiency across the entire care chain and set new standards for digital innovation in the healthcare sector. The foundation will be proven SAP technologies and products such as SAP Business Suite, SAP Business Data Cloud (SAP BDC), SAP Business Technology Platform (SAP BTP), and SAP Business AI. These core elements help create a unified, compliant, open, and expandable base for the more-secure exchange and use of data as well as for operating AI models in a controlled environment.
Together, the companies also plan to build a sovereign, European solution for an integrated healthcare ecosystem that supports the integration of modern hospital information systems (HIS) based on SAP’s “AnyEMR” strategy. Interfaces based on open industry standards such as HL7 FHIR will enable the more-seamless connection of HIS, electronic medical records (EMRs), and other medical applications.
“Together with SAP, we can accelerate the digital transformation of the German and European healthcare systems and enable a sovereign European solution that is so important in today’s global landscape. We are making data and AI everyday companions that are secure, simple, and scalable for doctors and hospital teams. This creates more room for what truly matters: caring for patients,” says Michael Sen, CEO of Fresenius.
“With SAP’s leading technology and Fresenius’ deep healthcare expertise, we aim to create a sovereign, interoperable healthcare platform for Fresenius worldwide. Together, we want to set new standards for data sovereignty, security, and innovation in healthcare. Thanks to SAP, Fresenius can harness the full potential of digital and AI-supported processes and sustainably improve patient care,” says Christian Klein, CEO and Member of the Executive Board of SAP SE.
As part of the joint transformation project, both companies plan to invest a mid three-digit million euro amount in the medium term to consistently drive the digital transformation of the German and European healthcare system through the use of digital and AI-supported solutions.
The partnership is implemented through several forms of collaboration. These include joint investments in startups and scaleups, joint technological developments, and close cooperation within coordinated governance structures between the two companies.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Worldwide
The people behind cancer care
On today’s World Cancer Day, Fresenius highlights what individualized cancer care means in practice. One patient’s story shows why seeing the whole person behind the diagnosis matters across the entire patient journey.
Worldwide
When Art Becomes Measurable
How Quirónsalud explores the impact of images on our well-being and the implications for new approaches in patient care
Worldwide
Comprehensive Care and Compassion: Fresenius' Commitment in Breast Cancer Treatment
Fresenius highlights its commitment to delivering excellent patient care and advancing medical innovation. One patient’s story shows how we bring hope and compassion when it matters most.
Worldwide
Earlier detection, more targeted treatment: Helios sets new standards in diagnosing lung cancer
Doctors are already setting new standards in the early diagnosis of disease with the robot-assisted “Ion endoluminal system” for bronchoscopy.
Worldwide
Antimicrobial resistance is on the rise: How Fresenius responds across all businesses
Antimicrobial resistance (AMR) is a growing global threat. Fresenius is stepping up, through responsible manufacturing, hospital hygiene, and targeted antibiotic use, to help ensure these life-saving medicines remain effective.
Worldwide
On World Prematurity Day:
A little medical miracle at the Helios hospital in Pforzheim
Worldwide
Walking in a Patient’s Shoes
How Fresenius Kabi is using immersive simulations to deepen understanding of chronic illness.
Worldwide
Celebrating 50 Years of Fresubin
This year marks a major milestone in our company’s history: the 50th anniversary of Fresubin®. What began as a clinical solution in 1975 has grown into a trusted and comprehensive enteral nutrition product brand for patients around the world.
Worldwide
More time for patients thanks to AI in the consulting room
With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine.
Worldwide
Sustainability at Fresenius: Three questions for Mapi Henríquez de Armas, Director Sustainability at Quirónsalud
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
Germany
First meeting of the year for the Sustainability Advisory Board in Friedberg
Our Sustainability Advisory Board got together for the first meeting of this year at Fresenius Kabi’s production and logistics site in Friedberg.
Worldwide
How Fresenius employees help people with cancer in every phase of the disease
They serve patients beyond expectations and always give their best – not just in the fight against cancer, but also when striving for the highest possible quality of life.
Worldwide
Sustainability at Fresenius: Five questions for Sarah Tix, Head of Group Sustainability
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
Germany
“The new ADC medicines represent a real revolution in treatment. This promising therapy can give many patients new hope.”
Professor Dr. Michael Untch from Helios Hospital Berlin-Buch explains how the new antibody-drug conjugates (ADCs) are changing the fight against cancer.
USA
“The flexibility of our Lovo and Cue cell processing systems was the key to success!”
Read our interview with Chris Wegener, to find out more about the device development for CAR-T cell therapy at Fresenius Kabi.
Germany
CAR-T cell therapy: Revolutionary chances of a cure, but costs still too high
How Fresenius Kabi is revolutionizing the treatment of cancer patients with the help of the Lovo and Cue cell processing systems.
Germany
“We combine various innovative solutions to achieve better patient outcomes step by step.”
Helios Hospital Berlin-Buch is one of the first hospitals in Germany to use augmented reality in the operating room.
Europe
Fresenius is a new partner of the Städel Museum
By supporting the renowned museum foundation, the healthcare company demonstrates its social responsibility. The partnership is at the same time a clear commitment to Frankfurt and the Rhine-Main region.
Germany
"Immunotherapies: Boosting Cures and more Patient Wellbeing"
Read our interview to find out what Dr. Anna Ossami Saidy, a doctor in training at the Helios Clinic Berlin-Buch, is currently researching.
Deutschland
Committed to Life: Fresenius now fresher and more modern with new brand identity
#FutureFresenius is making the company fit for the future. And the brand identity must reflect and support this.
Germany
Optimized colorectal cancer screening with AI
How artificial intelligence helps to detect polyps that can’t be seen by the human eye
Germany
CAR T cell therapy: Innovative therapy with the aid of genetically modified cells
“Personalized tumor medicine can be more effective at fighting tumors and produce beneficial therapies with fewer side effects.”
Germany
Welcome to our new podcast format: “Talk Time – CEO Insights with Michael Sen”!
Get to know more about how this year started for Michael Sen, his view on trends like AI in health care and health equity.
Germany
New year, good resolutions: Eating a vegan diet can do a lot for your health and the environment!
Hendrik Otto and Verena Kaiser from Helios explain the benefits of changing your diet
Europe
HOPE gives hope
Quirónsalud focuses on digitalisation to improve oncology patient care
Germany
"This is a tremendous win for the patients"
Interview with Prof. Iwasaki, winner of the Else Kröner Fresenius Prize for Medical Research 2023, endowed with 2.5 million euros.
Germany
Sustainably anesthetized
Anesthetic gas recycling reduces greenhouse gas emissions by 90 percent
Latin America
Planting trees and changing hearts
Fresenius Kabi Employees in the Dominican Republic are working to create a healthier environment.
Europe
‘Sometimes we understand each other without words’
Dr. Veronika Wolter is the first deaf person in Germany to achieve the position of chief physician. She herself uses a hearing prosthesis, and understands her patients very well.
Europe
A robot at the operating table
Fresenius Helios uses the latest robotic technology to make surgery gentler for patients – for example at Helios Hospital Erfurt in Germany.
Europe
Growing up with parenteral nutrition
How two brave adventurers from Switzerland are exploring the world step-by-step.
Europe
From a local pharmacy to a global corporation
As a leading global healthcare group we are dedicated to medicine and human health - values we have upheld since our founding as a pharmacy lab in 1912.
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments.
Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development.
The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation.
By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments.
Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development.
The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation.
By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.